Brainstorm Cell Therapeutics reported results from a multicenter, open-label phase 2 trial of NurOwn in progressive multiple sclerosis. Results showed a good safety and tolerability profile,…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.